Proficio Capital Partners LLC Invests $1.35 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

Proficio Capital Partners LLC acquired a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 25,271 shares of the company’s stock, valued at approximately $1,353,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. HealthInvest Partners AB bought a new stake in shares of Janux Therapeutics in the 4th quarter valued at about $2,078,000. Handelsbanken Fonder AB bought a new stake in shares of Janux Therapeutics in the 4th quarter valued at about $642,000. New York State Common Retirement Fund lifted its stake in shares of Janux Therapeutics by 84.6% in the 4th quarter. New York State Common Retirement Fund now owns 15,964 shares of the company’s stock valued at $855,000 after acquiring an additional 7,318 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Janux Therapeutics by 1.6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock valued at $2,043,000 after acquiring an additional 599 shares during the last quarter. Finally, Legato Capital Management LLC bought a new stake in shares of Janux Therapeutics in the 4th quarter valued at about $347,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JANX has been the subject of a number of recent research reports. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Leerink Partners boosted their target price on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $200.00 target price on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Scotiabank lowered their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. Finally, Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $88.00.

Janux Therapeutics Stock Performance

JANX stock opened at $30.64 on Friday. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -26.19 and a beta of 3.23. The business’s 50 day moving average price is $41.74 and its two-hundred day moving average price is $47.55. Janux Therapeutics, Inc. has a fifty-two week low of $29.63 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Buying and Selling

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 341,742 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were acquired at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the purchase, the director now owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. This trade represents a 3.67 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the sale, the insider now owns 82,139 shares in the company, valued at approximately $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,002 shares of company stock worth $2,684,703 in the last 90 days. Insiders own 29.40% of the company’s stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.